Statements (15)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Rapid-acting_insulin
gptkb:Novolog |
| gptkbp:appointed_by |
subcutaneous injection
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:brand |
gptkb:Novo_Log
|
| gptkbp:developed_by |
gptkb:Novo_Nordisk
|
| gptkbp:duration |
3 to 5 hours
|
| gptkbp:highest_point |
1 to 3 hours
|
| https://www.w3.org/2000/01/rdf-schema#label |
insulin aspart
|
| gptkbp:ingredients |
C256 H383 N65 O77 S
|
| gptkbp:is_used_for |
diabetes management
|
| gptkbp:premiered_on |
10 to 20 minutes
|
| gptkbp:type |
rapid-acting insulin
|